• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Cell Host Microbe . Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner

tetano

Editor, Senior Moderator
Cell Host Microbe


. 2021 Oct 13;S1931-3128(21)00465-0.
doi: 10.1016/j.chom.2021.10.003. Online ahead of print.
Prior infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-dependent manner


Roanne Keeton[SUP] 1 [/SUP], Simone I Richardson[SUP] 2 [/SUP], Thandeka Moyo-Gwete[SUP] 2 [/SUP], Tandile Hermanus[SUP] 2 [/SUP], Marius B Tincho[SUP] 1 [/SUP], Ntombi Benede[SUP] 1 [/SUP], Nelia P Manamela[SUP] 2 [/SUP], Richard Baguma[SUP] 3 [/SUP], Zanele Makhado[SUP] 2 [/SUP], Amkele Ngomti[SUP] 1 [/SUP], Thopisang Motlou[SUP] 2 [/SUP], Mathilda Mennen[SUP] 4 [/SUP], Lionel Chinhoyi[SUP] 4 [/SUP], Sango Skelem[SUP] 4 [/SUP], Hazel Maboreke[SUP] 5 [/SUP], Deelan Doolabh[SUP] 1 [/SUP], Arash Iranzadeh[SUP] 1 [/SUP], Ashley D Otter[SUP] 6 [/SUP], Tim Brooks[SUP] 6 [/SUP], Mahdad Noursadeghi[SUP] 7 [/SUP], James C Moon[SUP] 8 [/SUP], Alba Grifoni[SUP] 9 [/SUP], Daniela Weiskopf[SUP] 9 [/SUP], Alessandro Sette[SUP] 10 [/SUP], Jonathan Blackburn[SUP] 5 [/SUP], Nei-Yuan Hsiao[SUP] 11 [/SUP], Carolyn Williamson[SUP] 12 [/SUP], Catherine Riou[SUP] 12 [/SUP], Ameena Goga[SUP] 13 [/SUP], Nigel Garrett[SUP] 14 [/SUP], Linda-Gail Bekker[SUP] 15 [/SUP], Glenda Gray[SUP] 13 [/SUP], Ntobeko A B Ntusi[SUP] 16 [/SUP], Penny L Moore[SUP] 17 [/SUP], Wendy A Burgers[SUP] 18 [/SUP]



Affiliations

Abstract

The Johnson and Johnson Ad26.COV2.S single-dose vaccine represents an attractive option for coronavirus disease 2019 (COVID-19) vaccination in countries with limited resources. We examined the effect of prior infection with different SARS-CoV-2 variants on Ad26.COV2.S immunogenicity. We compared participants who were SARS-CoV-2 naive with those either infected with the ancestral D614G virus or infected in the second wave when Beta predominated. Prior infection significantly boosts spike-binding antibodies, antibody-dependent cellular cytotoxicity, and neutralizing antibodies against D614G, Beta, and Delta; however, neutralization cross-reactivity varied by wave. Robust CD4 and CD8 T cell responses are induced after vaccination, regardless of prior infection. T cell recognition of variants is largely preserved, apart from some reduction in CD8 recognition of Delta. Thus, Ad26.COV2.S vaccination after infection could result in enhanced protection against COVID-19. The impact of the infecting variant on neutralization breadth after vaccination has implications for the design of second-generation vaccines based on variants of concern.

Keywords: Ad26CoV2.S; Fc effector function; SARS-CoV-2; hybrid immunity; neutralization; vaccines; variants of concern.
 
Back
Top Bottom